Vascular endothelial growth factor (VEGF)-
Introduction
The vascular endothelial growth factor (VEGF) family of ligands and receptors has been the subject of intense study in the field of vascular biology for more than a decade. There is now a consensus that VEGFs are crucial for vascular development and neovascularization in both physiologic and pathologic processes. It has been suggested that the upregulation of VEGF-A underlies angiogenesis associated with diabetic retinopathy, tumor growth and metastasis, and arthritis. Recent studies revealed that VEGF-A also promotes the progression of atherosclerosis 1) . This review outlines our current knowledge pertaining to the signal transduction properties of VEGF receptors with particular focus on VEGF receptor-2 and its role in atherogenesis.
VEGF Family Members and VEGF Receptors
There are four different isoforms (121, 165, 189 and 206 amino acids in humans) of VEGF-A, which are generated by alternative splicing of a single premRNA species 2) . VEGF-A was first identified as a vascular permeability factor 3) , and later described as an endothelial cell mitogen 4, 5) . Intense research has clarified the role of VEGF-A in vascular development and as an inducer of endothelial cell migration and survival. Several mammalian VEGF-related proteins, VEGF-B, -C, -D, -E and placenta growth factor (PlGF) have been described. These VEGFs bind with different affinities to three related receptor tyrosine kinases, VEGF receptor-1 (VEGFR-1), VEGFR-2 and VEGFR-3 (Fig. 1) . All VEGF-A isoforms bind to both VEGFR-1 and VEGFR-2, whereas PlGF and VEGF-B are selective ligands for VEGFR-1. VEGF-C and VEGF-D interact with both VEGFR-3 and VEGFR-2, whereas VEGF-E is a selective ligand for VEGFR-2.
The binding of VEGF to the receptors induces receptor dimerization and activation, resulting in the transduction of signals that influence cellular func-tions. Although both VEGFR-1 and VEGFR-2 are expressed in the vascular endothelium, the angiogenic activities of VEGFs are transduced mainly through VEGFR-2 2)
. These activities include the proliferation, survival, migration and permeability of vascular endothelial cells. The targeted inactivation of either VEGF-A or VEGFR-2 interferes with angioblast differentiation and consequently with vasculogenesis [6] [7] [8] . The critical nature of the correct expression of VEGF-A was confirmed by the finding that the absence of only one of the two alleles leads to abnormal vascular development and embryonic lethality. VEGFR-1-deficient mice also exhibit embryonic lethality due to the obstruction of vessels by an overgrowth of endothelial cells 9) . In contrast, deletion of the intracellular domain of VEGFR-1 is compatible with normal vascular development 10, 11) , suggesting that VEGFR-1 acts as a decoy by binding and neutralizing VEGF-A in the absence of catalytic activation. VEGFR-1 is also expressed on monocytes, and its activation leads to chemotaxis in monocytes 11, 12) . VEGFR-3 is expressed mainly in lymphatic endothelium and is involved in the lymphangiogenesis, but it is also expressed in certain normal vessels and tumor vessels and plays an important role in vascular development 13) .
VEGFR-2 Signal Transduction and Function
VEGFR-2 signal transduction appears to follow the consensus scheme for the activation of receptor tyrosine kinases. The binding of the VEGF induces receptor dimerization, which is dependent on the Ig-like domain 3 of the extracellular domain of VEGFR-2 [14] [15] [16] . The locations of tyrosine-phosphorylation sites in the intracellular domain of VEGFR-2 are shown in Figs. 2-4. To date, Y951 in the kinase-insert domain 17) , Y1054 and Y1059 in the kinase domain 18, 19) and Y1175 and Y1214 in the C-terminal tail of VEGFR -2 20) have been identified as major autophosphorylation sites. In addition, Y1305, Y1309 and Y1319 in the C-terminal tail are thought to be a minor phosphorylation sites 17) . Y1054 and Y1059 are involved in the regulation of the receptor tyrosine kinase, since the mutation of Y1054 and Y1059 to phenylalanine residues leads to the loss of kinase activity 18, 19, 21) . Phosphorylation at Y1175 in the C-terminal tail allows the binding, phosphorylation and activation of phospholipase C 1 (PLC -1) 20) , ultimately leading to Ca 2 influx and the activation of protein kinase C (PKC) (Fig. 2) . The activation of PKC mediates cell proliferation signals via the The VEGF ligand family includes VEGF-A, -B, -C, -D, -E and placenta growth factor (PlGF), all of which bind in a specific manner to three different receptor tyrosine kinases, VEGFR-1, -2 and -3. Both PlGF and VEGF-B are selective ligands for VEGFR-1, whereas VEGF-A binds to both VEGFR-1 and VEGFR-2. VEGF-E is a selective ligand for VEGFR-2. VEGF-C and -D interact with both VEGFR-2 and VEGFR-3. Although both VEGFR-1 and VEGFR-2 are expressed in vascular endothelium, their angiogenic activities are transduced mainly through VEGFR-2. VEGFR-1 is also expressed on monocytes and macrophages, and its activation leads to cell migration. VEGFR-3 is expressed mainly in lymphatic endothelium and is involved in lymphangiogenesis.
extracellular signal-regulated kinase (ERK) pathway in cultured endothelial cells. Phosphorylated Y1175 also binds the adapter molecules Shb 22) and Sck 23) , indicating that Y1175 interacts with multiple signaling molecules. Shb mediates the activation of phosphoinositide 3' kinase (PI3-kinase) and the assembly of focal adhesions, which regulates VEGF-A-induced cell migration 22) (Fig. 3) . Thus, Y1175 appears to be an important phosphorylation site regulating both VEGFinduced cell proliferation and migration. A recent study showed that a knock-in mutation of Y1173 (corresponding to Y1175 in human VEGFR-2) to phenylalanine in the VEGFR-2 gene results in embryonic lethality due to severe defects in endothelial and hematopoietic cells similar to those observed in VEGFR-2-null mice 24) . Y1214 in the C-terminal tail contains a putative pY-D-N-T sequence that matches the Grb2 SH2-binding motif 25) . Although Grb2 is a major upstream stimulator of the Raf-1-MEK-ERK cascade, it is controvertible that Y1214 is required for VEGFinduced ERK activation 20, 26) . Recently, it was shown that the phosphorylation of Y1214 is required for the activation of Cdc42 and p38 mitogen-activated protein kinase (p38 MAPK), which mediate VEGF-induced actin reorganization 27) . Mice with a mutation of Y1212 (corresponding to Y1214 in human VEGFR-2) to phenylalanine are viable and fertile, indicating that Y1214 signaling is not critical for vascular development in mouse embryos 24) . The phosphorylation of Y951 in the kinase-insert domain binds to an adapter molecule, T-cell-specific adaptor protein (TSAd). TSAd is equivalent to VEGF receptor-associated protein (VRAP) 28) , Rlk and Itk-binding protein (RIBP) and Lck adaptor (LAD). TSAd was initially identified in T lymphocytes and is expressed at high levels in vascular endothelial cells. Y951-mediated coupling of VEGFR-2 and TSAd is critical for VEGF-induced actin reorganization and cell migration but not for VEGF-induced cell proliferation of endothelial cells 17) . Targeted disruption of the TSAd gene in mice does not cause any major developmental abnormalities 29) ; however, when TSAd-null mice were injected with fibrosarcoma cells, tumor vascularization and growth were impaired 17) , indicating Activated VEGFR-2 is associated with adaptor proteins TSAd, Shb and Grb2 via Y951, Y1175 and Y1214, respectively. Phosphorylated TSAd binds to Src and regulates VEGF-A-induced actin reorganization and cell migration. The PI3-kinase/Rac/Rho pathway is thought to be downstream of TSAd. Other components implicated in VEGFR-2-dependent cytoskeletal regulation and cell migration include FAK and p38 MAPK. Activated Shb mediates VEGF-A-induced FAK phosphorylation followed by the recruitment of actinanchoring proteins to focal adhesion plaque. VEGF-A-induced activation of p38 MAPK is required for Y1214 phosphorylation. Thus, multiple pathways appear to regulate endothelial cell migration.
that Y951/TSAd signaling is critical for pathological angiogenesis. VEGFR-2 also activates PI3-kinase, which results in increased levels of phosphotidylinositol-3,4,5-trisphosphate (PIP3) and the activation of several important intracellular molecules, including Akt and the small GTP-binding protein Rac. The Akt pathway regulates cellular survival by inhibiting involvement in pro-apoptotic pathways, such as B-cell lymphoma 2-associated death promoter homologue (BAD) and caspase 9 30) (Fig. 4) . The VEGF-A-induced complex formation of vascular endothelial cadherin (VE-cadherin), VEGFR-2, -catenin and PI3-kinase appears to be critical for VEGFR-2-dependent endothelial survival 31) . The Akt pathway also activates endothelial nitric oxide synthase 32, 33) , followed by the generation of nitric oxide, which is thought to increase vascular permeability.
VEGF/VEGFR Signaling and Atherosclerosis
Atherosclerosis is considered an angiogenesis-associated disease, similar to malignant tumors, because many studies have shown that intimal neovascularization is associated with plaque development and stability [34] [35] [36] [37] . VEGF-A/VEGFR signaling likely plays a central role in intimal neovascularization. VEGF-A is expressed predominantly in aggregating macrophages in atherosclerotic lesions 38) , and the expression of VEGF-A increases during atherogenesis 39) . The administration of VEGF-A protein to apolipoprotein-Edeficient mice promotes angiogenesis and enhances neointimal size in atherosclerotic plaques 1) . These activities are thought to be mediated by VEGFR-2. In addition, endogenous VEGF-A from atherosclerotic lesions induces the direct migration of circulating monocytes via VEGFR-1 and promotes the accumulation of macrophages in developing plaques. Taken together, these data indicate that VEGF-A enhances atherogenesis via the stimulation of vasa vasorum growth that can recruit inflammatory cells and also via the stimulation of direct migration of monocytes/macrophages in the plaque. The administration of anti-VEGFR-1 antibody to apolipoprotein-E-deficient mice reduces plaque development and increases plaque stability via the impaired infiltration of monocytes into the neointimal area 40) . Given the role of VEGF/VEGFR signaling in the development and instability of atherosclerotic plaques, anti-VEGF therapy could be useful for the prevention of progression of tumors and atherosclerosis. Phosphorylation sites, such as Y951 and Y1175, that influence VEGFR-2 activity may be useful as targets for anti-angiogenic therapies. Activated PI3-kinase induces Akt phosphorylation. The Akt pathway regulates cellular survival by inhibiting pro-apoptotic pathways, such as those involving BAD and caspase 9. Complex formation of VE-cadherin, VEGFR-2, -catenin and PI3-kinase in response to VEGF-A is required for Akt-dependent cell survival signaling.
